[2025] NSWCATOD 145
General information, not legal advice.
NCAT Occupational
2025-10-30
Original judgment source is linked above.
(1) The inappropriate compounding and dispensing of ketamine between 2014 and 2015 on 312 occasions (Complaints Two and Four).
(2) Permitting hormones and peptides to be dispensed to a patient without knowing the patient's medical condition or having a reasonable basis for believing the peptides were prescribed for an appropriate therapeutic purpose (Complaint Five).
(3) Shortly before October 2014, supplying or permitting the supply of melatonin and thymosin beta 4 (which was not an approved drug) to a patient where the patient did not have a prescription for those drugs (Complaint Six).
(4) Between October 2010 and July 2014 permitting 12 prescriptions of the drug HCG to be compounded and dispensed on prescriptions from certain doctors for weight loss in circumstances where, amongst other things, the HCG was not supplied for a recognised therapeutic purpose (Complaint Seven).
(5) Between January and September 2014 permitting peptides to be dispensed on approximately 168 occasions, sometimes in combination with other peptides, without knowing the patients' medical conditions or having a reasonable basis for believing the peptides were prescribed for an appropriate therapeutic purpose (Complaint Eight).
(6) Between June 2014 and May 2016 permitting 7,951 prescriptions for peptides to patients to be compounded and dispensed without knowing the patients' medical conditions or having a reasonable basis for believing the peptides were prescribed for an appropriate therapeutic purpose (Complaint Nine).
(7) Between June and December 2014 permitting different peptides to be dispensed in combinations to four patients in circumstances where the directions on the prescriptions were vague and insufficiently clear and without knowing the patients' medical conditions or having a reasonable basis for believing the peptides were prescribed for an appropriate therapeutic purpose (Complaint Ten).
(8) Between December 2015 and February 2016 permitting phentermine to be compounded and supplied to 184 patients in circumstances where Mr Knowles did not provide appropriate information about the compounded drugs and, amongst other things, without taking reasonable steps to establish that the medication was suitable for the patients supplied (Complaint Eleven).
(9) Between September 2015 and October 2016 permitting testosterone with chrysin to be compounded and dispensed to patients on approximately 418 occasions in circumstances where Mr Knowles had not done any clinical trials to satisfy himself as to the safety and efficacy of the formulation, contrary to Guideline 2 of the Pharmacy Board of Australia (PBA) guidelines on compounding of medicine where there was insufficient information about the topical exposure of chrysin to be satisfied about its safety (Complaint Twelve).
(10) Between September 2015 in October 2016 permitting testosterone and zinc to be compounded and dispensed to patients on approximately 418 occasions in circumstances where there was a commercially available approved product with the Australian Register of Therapeutic Goods (ARTG) and where compounding and dispensing testosterone cream was contrary to Guideline 2 of the PBA guidelines on compounding medicines. (Complaint Thirteen).
(11) Between July 2015 and April 2016 permitting a topical preparation containing testosterone with SARMS 22 (a drug not approved by the ARTG) without a reasonable basis to believe the addition of SARMS 22 had any material effect on the therapeutic purpose of the product (Complaint Fourteen).
(12) Between July 2014 and November 2016 permitting a topical preparation including testosterone and DHEA (a drug which was not approved and had never been registered on the ARTG) to be compounded and dispensed to patients in circumstances where there was a commercially available approved ARTG product, combining and dispensing the topical preparation was contrary Guideline 2 of the PBA guidelines on compounding medicines and where Mr Knowles had no reasonable basis to believe that the addition of DHEA had any material effect on the on the therapeutic purpose of the product (Complaint Fifteen).
(13) Particulars in Complaints Four and Eight to Fifteen were relied on individually to establish professional misconduct (Complaint Sixteen).
(14) From February 2002 to around October 2006 entering into an arrangement to conduct a pharmacy business with a non-pharmacist in contravention of s 25 of the Pharmacy Act 1964 (NSW) (since repealed) by entering into an arrangement with a party in around February 2002 whereby companies controlled by that party referred prescriptions for compounded pharmaceuticals to Mr Knowles and the profits generated from dispensing those prescriptions were paid to the companies controlled by that person until around October 2006 and by dispensing products pursuant to that arrangement for periods for February 2002 and April 2003 to October 2006 (Complaint Seventeen).
(1) The conduct of Mr Knowles which was the subject of Complaints Two to Fifteen was "significantly below the standard reasonably expected" of a practitioner of an equivalent level of training or experience, as defined by s 139B(1)(a) of the National Law: at [70].
(2) Mr Knowles was guilty of "unsatisfactory professional conduct" in respect of the established particulars of Complaints Two and Four to Fifteen, as defined by s 139B(1) of the National Law, and his conduct was unethical: at [74].
(3) In respect of Complaint Sixteen, there were 13 instances of unsatisfactory professional conduct, which, when considered together amounted to conduct of a sufficiently serious nature to justify suspension or cancellation of registration: at [79].
(4) Mr Knowles contravened s 25 of the Pharmacy Act 1964 during a period when to do so was professional misconduct under s 19A of the Pharmacy Act 1964.
(5) If Mr Knowles was still registered as a pharmacist, the Tribunal would have cancelled his registration, and such an order was warranted by the extent, length and nature of the admitted conduct: at [93].
(1) Throughout his 35 years of practice, he had never received a complaint or report of harm from a patient or treating doctor.
(2) He had consistently dispensed millions of prescriptions without incident and, in agreeing to withdraw the application against his co-accused pharmacist manager, the HCCC acknowledged that there was no evidence of direct patient harm as a result of the conduct and the matter did not raise any novel principles that would justify depriving the Tribunal and the Council of resources to hear other cases.
(3) At the time of the allegations, ACP was the most accredited compounding pharmacy in Australia, being the only pharmacy to receive APB Guideline USP797 and USP795 accreditation from an external auditor (together the "USP standards"). The staff were Good Manufacturing Practice (GMP) trained by TGA (Therapeutic Goods Administration) approved educators, with courses co-written by himself and his co-accused pharmacist manager.
(4) In 2015, after receiving the complaint, Mr Knowles made the decision to elevate his operations by constructing a GMP facility licenced by the TGA for sterile and non-sterile compounding. He achieved this in October 2020 while addressing ongoing inquiries from the HCCC and the Pharmacy Council of Australia.
(5) Upon receiving the TGA licence for ACPharm, he closed the ACP compounding facility in 2020. He also licenced the ACP analytical lab, which had conducted quality control testing for ACP compounding medicines for 10 years. This unique facility was staffed with exceptional pharmacists.
(6) During this period, Mr Knowles experienced one of his greatest achievements, being awarded the title of the Fellow of the Australian College of Pharmacy in April 2019 for his contributions to modern compounding, research and education. He also received a certificate of appreciation from the University of Sydney Pharmacy Department for his contributions to the education and mentorship of numerous pharmacy students in GMP and manufacturing practices at ACP. He also obtained TGA clinical trial approval for his facility to develop an Australian made novel antibiotic combination for head trauma patients in ICU as prevention for pneumonia morbidity. This was a global 14,000 patient HREC Phase 3 trial sponsored by George Global Research Institute which ran from 2015 to 2021 with the goal of helping people in second world countries.
(7) Mr Knowles and his wife relocated to the NSW Central Coast in September 2021, and he continued working in his licenced facility as an unregistered pharmacist and general manager of operations until his retirement in October 2023.
(8) After becoming aware of the critical shortage of pharmacists in his local community on the Central Coast, leading to some local pharmacies temporarily closing due to the lack of registered locums, he decided to return to the pharmacy profession when possible.
(9) He commenced employment at Priceline Kincumber as a shop assistant under the supervision of Trent Playford and Victor Frangos in January 2024. He made significant efforts to become a valued and respected part of the team while complying with all relevant requirements for general registration as a pharmacist. To demonstrate his commitment to his employers and build on the progress made in his first year, Mr Knowles focused on enhancing his knowledge and expertise in community pharmacy arrangements.
(10) He assumed additional responsibility as a pharmacist under supervision, which included training junior staff and delivering small lectures on the quality use of medicines to local community groups. He now regularly worked on Thursdays and Fridays at Priceline Kincumber and Wednesdays at Amcal West Gosford. He had completed over 1400 hours under supervision and has received written references from the owners and managers of both stores.
(11) During this period, he rejoined the Pharmaceutical Society of Australia to complete his continuing education and has accrued over 60 continuing professional development points in the current year. He has reviewed the most recent pharmacy practice guidelines and regulatory changes.
Reinstatement - relevant law and legal principles
(a) decide that if the person were still registered the Tribunal would have suspended or cancelled the person's registration; and
(b) if the Tribunal would have cancelled the person's registration, decide that the person is disqualified from being registered in the health profession for a specified period or until specified conditions have been complied with; and
(c) require the National Board with which the person was registered to record the fact that the Tribunal would have suspended or cancelled the person's registration in the National Register kept by the Board.
(1) The appropriate review body must conduct an inquiry into an application for review and may then do any of the following--
(a) dismiss the application;
(b) make an order ending or shortening the period of the suspension concerned;
(c) make a reinstatement order;
(d) make an order altering or removing the conditions to which the person's registration is subject, including by imposing new conditions;
(e) make an order--
(i) ending or shortening the period of a prohibition order; or
(ii) altering or removing the conditions to which the person is subject under a prohibition order, including by imposing new conditions.
...
(3) A "reinstatement order" is an order that the person may be registered in accordance with Part 7 if--
(a) the person makes an application for registration to the National Board; and
(b) the relevant National Board decides to register the person.
(3A) Any condition imposed on a person's registration by the National Board under Part 7 applies but only to the extent that it is not inconsistent with conditions imposed or altered by the appropriate review body under subsection (4).
(4) The appropriate review body may also impose conditions on the person's registration or alter the conditions to which the person's registration is to be subject under the reinstatement order.
(5) The order on a review under this section may also provide that the order is not to be reviewed under this Division until after a specified time.
(1) A review under this Division is a review to determine the appropriateness, at the time of the review, of the order concerned.
(2) The review is not to review the decision to make the order, or any findings made in connection with the making of that decision.
(3) In addition to any other matter the review may take into account, the review must take into account any complaint made or notified to a Council or a National Board, or a former Board under a repealed Act, about the person, whether the complaint was made or notified before or after the making of the order that is the subject of the review and whether or not the complaint was referred under Subdivision 2 of Division 3 or any other action was taken on the complaint.
(4) A Council and the Commission are entitled to appear at any inquiry conducted by the Tribunal under this Division.
16. The proceedings below were an application, by way of review under s 163A of the National Law, for reinstatement. Such an application is an inquiry into present fitness, and not a review of the original decision in which the practitioner was deregistered. Although, under earlier legislation, the Medical Tribunal could revisit the earlier decision, the present legislation precludes that course, as s 163C of the National Law provides as follows:
[text of s 163C(1) and (2) omitted]
17. In conformity with s 163C(1), the task of the review Tribunal on a reinstatement application is therefore to determine the appropriateness of an order reinstating the applicant, as at the date of hearing the application. In performing that task, the Tribunal must have regard to the objectives and guiding principles of the National Law, which relevantly include the protection of the public by ensuring that only those practitioners who are suitably trained and qualified to practise in a competent and ethical manner are registered, the paramount consideration being the protection of the health and safety of the public.
18. The position of an applicant for reinstatement is disadvantaged by reason that presumptions of fitness, which might otherwise arise from an absence of contrary suggestion, do not operate for the benefit of an applicant who has been deregistered on the basis of unfitness. An applicant for reinstatement bears the onus of demonstrating that he or she can be trusted to practise in a way that conforms to the professional standards expected of a health practitioner and presents no risk to the safety of the public and their confidence in the profession.
19. Thus the essential task of an applicant for reinstatement is to show that he or she is no longer unfit. In this case, given that the sole basis of the appellant's deregistration was lack of competence by reason of an impairment, what the appellant had to demonstrate was that she was no longer unfit by reason of an impairment of such a nature and degree as impaired her mental capacity to practise. On that issue, she bore the onus of proof.
[citations omitted]
(1) His reflections in 2025 on professional practice standards (Ex A3).
(2) Certificate of Fellowship to the Australian College of Pharmacy (awarded 29 January 2020) and Certificate of Appreciation from the University of Sydney School of Pharmacy (22 October 2019) (Ex A4).
(3) Professional reference from Fiona Wolski dated 4 June 2025 (Ex A5).
(4) Professional reference from Trent Playford dated 5 June 2025 (Ex A6).
(5) Document relating to licences and accreditation for Australian Life Science Pharma and Verita Pharma Pty Limited (Ex A7).
(6) Curriculum Vitae for Mr Knowles (Ex A8).
(7) Reference letter from Michael Anderson dated 10 August 2025 (Ex A9).
(8) Response to HCCC written submissions filed 13 August 2025 (Ex A10).
(1) He understood and accepted the Tribunal's decision; he fully acknowledged the seriousness of his professional misconduct and the potential implications for patient safety and public trust in the pharmacy profession at the time and deeply regretted any actions that may have contributed to patient risk or diminish these standards of the pharmacy profession.
(2) Mr Knowles now realises fully the deficiency in his decision-making and training that led to these outcomes. To this end, he has over the past 10 years, since receiving the initial complaint, been committed to addressing the issues with "humility, accountability and resolve to uphold the highest standards of practise moving forward".
(3) Mr Knowles was an officer of an TGA registered facility and is now fully aware of his obligations under the Poisons and Therapeutic Goods Act 1966 and the regulations. While he made genuine efforts to comply with the relevant regulations and legislation, there were instances where he misinterpreted and, on reflection, ignored or flouted certain requirements. He now recognises that this led to actions that were not aligned with ethical or professional standards.
(4) Since this time, Mr Knowles has taken steps to educate himself more thoroughly and he has developed a clearer understanding of his legal and ethical obligations. He is committed to approaching all future decisions with greater diligence and integrity, ensuring that he will seek clarification if he needs it and he will act in accordance with both the letter and spirit of the law.
(5) In relation to the complaints about understanding safety requirements of off-label dispensing and essential risk assessment required before dispensing (Complaints 4, 7, 8, 10 and 12 to 15), he has undertaken training in risk management and clinical trial medication supply. The experience of a five year project with the TGA registered facility of Australian Life Sciences Pharma has given him new insights into the inadequate precautions and risk management that he conducted at ACP. For instance, he would have not proceeded with dispensing the off-label medications and acknowledges that some of his past decisions, while not intentionally harmful, were made based on a flawed understanding of his ethical and legal obligations.
(6) In relation to the complaints about a pharmacist's responsibilities to understand the intended purpose, patient needs and appropriate quantities of medication regardless of having a legal prescription (Complaints 2, 5, 6 and 9 to 11), he now understands the intended meaning of quantity and purpose and understands that the phrase "recognised therapeutic standard" underscores the expectation that pharmacists will exercise professional judgement to ensure that any supply aligns with evidence based therapeutic standards. He admits that his judgement in the circumstances outlined in the complaint was below the standard expected of a pharmacist of his training and experience.
(7) Mr Knowles accepts that compounded medicines, including peptides, are subject to additional scrutiny. He also accepts that his decision to compound various peptides and creams did not include sufficient evidence for their safe compounding. Mr Knowles states that he has changed his risk assessment process and would not compound these medicines given his learned insight. He further states that he now understands that his supply of compounded peptides, even on legal prescriptions, may not have met the recognised therapeutic standard required under the law, for which he now takes full responsibility.
(8) In relation to Complaint 17, Mr Knowles states that he successfully defended this complaint about pecuniary interest in the Supreme Court but now understands that he must consider further the implications to the profession as well as the pure legality of the situation. He states that if he was presented with this "opportunity" again, he would make a totally different decision.
(9) Mr Knowles deeply regrets any potential risk that his actions may have posed to patients and that, by compounding peptides, he inadvertently contributed to a practice that could undermine public confidence in the safety of compounded medicines. He states that pharmacist must act as gatekeepers, critically evaluating prescriptions to prevent inappropriate supply and that his failure to adequately scrutinise the therapeutic appropriateness of the peptides he supplied was a deviation from his professional duty. He acknowledged the supply of injectable ketamine for an off-label indication of treatment resistant depression may not satisfy the rigorous guidelines surrounding clinical trials. He further acknowledges that he did not have specific robust evidence to support the addition of certain medications.
(10) The complaints have prompted him to undertake a significant reflection on his practise and decision making process and he acknowledges that he should have been more vigilant in ensuring compliance with the relevant legislation and guidelines. To address these shortcomings, he has taken proactive steps by enrolling in the Pharmaceutical Society of Australia's Pharmacy Practice Guidelines in December 2024 and the TGA's 2020 public discussion for development of sterile compounding guidance. He has initiated a comprehensive audit of his dispensing practices from the time of receiving the complaints until he closed his compounding pharmacy in June 2020. He has also sought guidance and supervision from senior colleagues over the past 18 months and has implemented a more rigorous documentation process to record his rationale for supplying compounded medicines. He built and licenced a TGA sterile compounding facility and digital GMP documentation system between 2015 and 2020 which vastly increased his knowledge of compounded medicine.
(11) Mr Knowles has not practised for over four years and at the age of 67 years old, he has no intention of practising as a proprietor of a compounding or non-compounding pharmacy. He wants to be reregistered to respond to the critical shortage of a registered pharmacist in the Central Coast region.
(12) He is prepared to give further undertakings that he will not participate in modern or complex compounding other than that contained in the Australian Pharmaceutical Formulary (APF). He also undertakes to only work as an employed pharmacist and not to take any proprietor or ownership role in a pharmacy business.
Mr Knowles' reflections on continuing professional development
Mr Knowles' response to the HCCC's written submissions
(1) Disagrees with the HCCC's "sparse description" of his grounds for reinstatement and further states that he has a long term commitment to remediation, he has gained new insight into his previously inadequate appreciation of the potential risks associated with extended medical supplies to patients, he let his passion for pharmacy and emotional desire to be perceived as helpful cloud his decision making, and he has undertaken a 10 year process of learning and contributing back to the industry as evidenced by the "humbling recognition" by two groups of his peers about his contributions to the profession.
(2) By way of expanding upon his long term commitment to remediation, Mr Knowles states that he has over the nearly 10 years since the original complaint in 2015 reflected upon his decision making and conduct leading to the 2015 complaint and has, over the past 10 years, taken steps to gain the necessary insight. He notes that the complaint of December 2019 was a second amendment of the original complaint and so he believes his insights and knowledge gained should be evaluated since 2015. Mr Knowles points to the fact that his practice was independently audited and accredited to USP standards and that he was the only pharmacist in Australia to achieve this.
(3) He notes that in his affidavit of 1 December 2020 in the disciplinary proceedings (referred to the HCCC submissions), he stated that he was not registered and that he undertook never to apply to be registered as a pharmacist in any jurisdiction. However, he gave this undertaking in the context of the HCCC agreeing to the complaint against his "co-accused" pharmacy manager being withdrawn. Mr Knowles also applied for the Tribunal not to make an inquiry into the complaint, and he attempted to negotiate the same arrangement. When this was not agreed to, he decided to rescind his offer at that time. The representation that he made in 2020 that he did not wish to reapply for registration was based on his circumstances at the time but since that time he has missed being a pharmacist serving in his local community. This should not be held against him.
(4) Mr Knowles also notes that the HCCC raises concerns about his employment in the past three years and about whether he was acting as an unregistered pharmacist. Mr Knowles states that the reference in his affidavit to working as an unregistered pharmacist was to indicate that he did not hold himself out to be a registered pharmacist. His role did not require him to make clinical decisions or deal with customers or patients. When he commenced working, his employers had full knowledge of his unregistered status and employed him as a pharmacy assistant grade 4 He has not worked in a role as a pharmacist and recognises that there is a distinction between a pharmacy assistant and an unregistered pharmacist.
(5) In his view, an unregistered pharmacist is someone who has completed pharmacy education but is not registered with AHPRA. They may work under the supervision of a registered pharmacist, but the scope of practice is limited to that of pharmacy assistant. A pharmacy assistant can work under the supervision of a registered pharmacist, but the assistant is limited to non-clinical tasks such as managing inventory, assisting customers and performing basic sales functions. His role has been focusing on supporting the registered pharmacist and store managers and to ensure compliance with pharmacy laws and regulations. If a patient has questions about their medication, they have health concerns or complex queries or there is need to discuss medication management, he refers those questions to the pharmacist.
(6) Mr Knowles states that he has acted in good faith and he has not represented himself to the general public as a qualified pharmacist or a pharmacist under supervision.
(7) Mr Knowles acknowledges the importance of adhering to legal requirements and states he has taken steps to comply with the National Law. He admits that the conduct warranting the disqualification was serious and occurred over a significant period of time. He further states that one of the reasons for the significant period for the conduct was that he had on several occasions visits from the professional standards unit (PSU) of the NSW Health Department during 2010 and 2015 but at no time did officers tell him he was contravening the legislation until nearly five years later. He states that if he had been told this in 2010, he would have immediately stopped his practice.
(8) Mr Knowles attributes much of his failure to uphold the requisite standards to a misinterpretation or a lack of understanding of the expectations of the governing standards that the period of conduct to the lack of immediate enforcement by PSU before December 2015. He further states that the fact that he had undergone extensive risk assessment and pharmacy practice guidance training confirms his ethical and risk management commitment as a pharmacy professional.
(9) Mr Knowles states that he takes full responsibility for his actions and now has a full understanding and insight of the risks he posed to the safety of his patients. His focus on the fact that there was no complaint from a customer or treating doctor relates to one of the reasons reportedly given by the HCCC in relation to his "co-accused', Mr Plummer. He submits that these statements do not demonstrate his failure to take account of risks associated with his conduct. He has undertaken many professional development courses both before and after the disciplinary proceedings and the HCCC "cherry picks" the fact that only two of the courses directly addressed the conduct which led to the original disciplinary proceeding. The HCCC has also excluded significant courses that he undertook prior to his 2025 CPD year, his 10 year process to change his practice regarding risk assessment and ethical decision making and his voluntary community service at local care homes, Central Coast Catholic health services and as a life force coach for the prostate Cancer Foundation of Australia. He has already achieved 61 CPD points in this year alone.
(10) Mr Knowles states that he has completely admitted the conduct of the complaint and it is "mischievous" of the HCCC to describe his evidence as merely "considerable progress". The HCCC has neglected to acknowledge the total revamp of his compounding practice between 2015 and 2020.
(11) Mr Knowles states that the restrictions he has proposed, which limit compounding to that contained in the APF, are reasonable and demonstrate his respect for regulatory standards.
• the applicant bears the onus of proving that he is a fit and proper person to be engaged in the profession of nursing as an endorsed enrolled nurse (see [41] and the authorities there referred to);
• the standard of proof to be applied by the Tribunal is the civil standard of proof, the balance of probabilities, tempered by the requirements of Briginshaw v Briginshaw [1938] HCA 34; (1938) 60 CLR 336); (see [41] and the authorities there referred to; see too In Re Jason Martin [2010] NSWMT 13 at [41]);
• the purpose of the jurisdiction is "not punishment or further punishment" of the former practitioner, rather the jurisdiction is exercised is for the protection of the public (see [47] and the authority there referred to);
• the power to reinstate should "be exercised with great caution and only upon solid and substantial grounds" (see [48] and the authority there referred to);
• there is no public interest in denying forever the chance of redemption and rehabilitation to former practitioners. The public is better served if, in appropriate cases, those who have offended, once they have affirmatively proved reform, are afforded a second chance (see [49] and the authority there referred to);
• in making an assessment of the applicant's worthiness and reliability for the future the Tribunal may draw inferences from what has happened in the past and, in particular, what led to their being removed from the Register. At [50] the Tribunal referred to In Re Jason Martin [2010] NSWMT 13 where the Medical Tribunal pointed out it is not "a question of what an applicant has suffered in the past. It is a question of his [her] worthiness and his [her] reliability for the future". That Tribunal noted the difficulty associated with predicting how a practitioner would behave in the future and remarked that "the decision in the particular case is to a greater or lesser extent dependent upon the Tribunal's assessment of the applicant".
Why have we decided to refuse Mr Knowles' application and to make a non-reviewable order?
3A The main guiding principle of the national registration and accreditation scheme is that the protection of the health and safety of the public must be the paramount consideration.
3b In the exercise of functions under a NSW provision, the protection of the health and safety of the public must be the paramount consideration.
51 We agree with the view expressed by the Tribunal in Ristevski at [70]-[71] that in conducting a review of a relevant order under s 163B of the National Law, there is a public interest in the Tribunal being assisted by the relevant practitioner Council or the Commission. Without a respondent in this class of matters, there is a risk that the Tribunal might only have available the self-serving evidence adduced by the applicant practitioner. The involvement of, to use the term coined in Ristevski, a "public interest respondent" in review proceedings, assists the Tribunal in discharging its obligation to ensure that all relevant material is disclosed so as to enable it to determine all relevant facts in issue: s 38(6)(a) of the Civil and Administrative Tribunal Act 2013 (NSW).
52 While we have considerable sympathy for Ms Ake**'**s position and the inevitable financial burden imposed by a costs order, the authorities have consistently stated that mere impecuniosity of the losing party is not a justifiable reason to departing from the usual rules in respect of costs: Health Care Complaints Commission v Philipiah at [42].
Provided the respondent conducts its case appropriately, it should be compensated regardless of whether the order is granted or refused.
The Tribunal may make a costs order in disciplinary proceedings or an appeal brought under the Health Practitioner Regulation National Law. Costs are generally awarded to the successful party unless there are disqualifying circumstances.
(1) Mr Knowles' application for reinstatement is dismissed.
(2) Mr Knowles is not entitled to seek a review for 12 months from the date of this order
(3) Mr Knowles is to pay the costs of the HCCC on an ordinary basis as agreed or assessed.
I hereby certify that this is a true and accurate record of the reasons for decision of the New South Wales Civil and Administrative Tribunal.
I hereby certify that this is a true and accurate record of the reasons for decision of the Civil and Administrative Tribunal of New South Wales.
Knowles
Health Care Complaints Commission [2025] NSWCATOD 145;
(1938) 60 CLR 336